Review
circRNA: A New Biomarker and Therapeutic Target for Esophageal Cancer

Katsutoshi Shoda 1, Yuki Kuwano 2, Daisuke Ichikawa 1 and Kiyoshi Masuda 3,*

1 First Department of Surgery, Faculty of Medicine, University of Yamanashi, Yamanashi 409-3898, Japan; kshoda@yamanashi.ac.jp (K.S.); dichikawa@yamanashi.ac.jp (D.I.)
2 Department of Medical Genetics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770-8503, Japan; kuwanoy@tokushima-u.ac.jp
3 Kawasaki Medical School, Okayama 701-0192, Japan
* Correspondence: kiyoshim@med.kawasaki-m.ac.jp; Tel.: +81-86-462-1111

Abstract: Circular RNAs (circRNAs) comprise a large class of endogenous non-coding RNA with covalently closed loops and have independent functions as linear transcripts transcribed from identical genes. circRNAs are generated by a “back-splicing” process regulated by regulatory elements in cis and associating proteins in trans. Many studies have shown that circRNAs play important roles in multiple processes, including splicing, transcription, chromatin modification, miRNA sponges, and protein decoys. circRNAs are highly stable because of their closed ring structure, which prevents them from degradation by exonucleases, and are more abundant in terminally differentiated cells, such as brains. Recently, it was demonstrated that numerous circRNAs are differentially expressed in cancer cells, and their dysfunction is involved in tumorigenesis and metastasis. However, the crucial functions of these circRNAs and the dysregulation of circRNAs in cancer are still unknown. In this review, we summarize the recent reports on the biogenesis and biology of circRNAs and then catalog the advances in using circRNAs as biomarkers and therapeutic targets for cancer therapy, particularly esophageal cancer.

Keywords: circRNA; esophageal cancer; biomarker; therapeutic target

1. Introduction

Covalently closed circular RNAs (circRNAs) are a large class of non-coding RNAs that are generated by a process called back-splicing. In 1976, the first circular RNA molecule (viroid) was discovered as a pathogen by Sanger sequencing [1]. After a few years, Hsu et al. [2] reported the presence of the circular form of RNA in the cytoplasmic extraction of several eukaryotic cells using electron microscopy. Since then, a variety of circular RNAs have been reported. In 1991, Nigro et al. discovered some abnormally spliced transcripts called “scrambled exons”, which originated from the candidate tumor suppressor gene deleted in colorectal cancer (DCC) and were produced by non-canonical splicing [3]. A year later, similar transcripts from the human ETS proto-oncogene 1, transcription factor (ETS-1) gene were reported [4]. In 1993, Cocquerelle et al. identified that these mis-splicing products from the ETS-1 and DCC genes are circular RNA molecules containing only normally spliced exons and are localized in the cytoplasm [5]. The second report in 1993 demonstrated that the Sry RNA molecules in cDNA and 5′RACE clones isolated from mouse testes have a circular structure [6]. This circular RNA represents the most abundant transcript in the cytoplasm and testis, indicating that it might be functional. Several other studies have documented that exon circularization can be induced in nuclear extracts in vitro [7,8]. In recent years, the advancement of high-throughput RNA sequencing (RNA-seq) followed by bioinformatic algorithms specialized for circRNAs has identified thousands of circRNAs in metazoans, including Drosophila, nematodes, mice, and humans, and have shown their tissue- and developmental-specific expression pattern [9–14].
Most circRNAs are generated by back-splicing, in which a downstream splice donor site is covalently linked to an upstream splice-acceptor site, and are abundant in the cytoplasm. Bioinformatic algorithms that identified circRNAs from long-read RNA-seq data revealed that more than half of the circRNAs span <5 complete exons and consist of only protein-coding exons, especially in 5′-untranslated regions (UTRs) [15]. In contrast to exon-derived circRNAs, failure in intron lariat debranching or internal intron retention during canonical splicing may produce circular intronic RNAs (ciRNAs) and exon–intron circular RNAs (EIciRNAs), respectively. These classes of circRNAs are abundant in the nucleus and act as stimulators of the transcription of their parental genes in cis [16,17].

In general, circRNAs are highly stable because of the covalently closed ring structure that protects them from degradation by exonucleases [10] and are more abundant in terminally differentiated cells, such as brains [11]. In contrast, the expression levels of circRNAs in highly proliferating cells, such as cancer cells, are often low, possibly because of the thinning out by cell proliferation [18].

Recent evidence has shown that circRNAs participate in many pathological processes, such as diabetes mellitus, Alzheimer’s disease, atherosclerosis, chronic inflammatory diseases, and cancer [19–23]. This review summarizes the recent reports on the biogenesis and biology of circRNAs. We also cataloged the advances in using circRNAs as biomarkers and therapeutic targets for esophageal cancer.

2. Biogenesis of circRNAs

Many studies have shown that circRNAs are expressed at much lower levels than their associated linear transcripts, and their expression levels do not simply correlate with their linear isoform expression, indicating a potential layer of unknown regulation [24]. Some studies have revealed that circRNA production strongly depends on the presence of canonical splice sites in bracketing exons and spliceosome assembly, indicating that circRNA biogenesis competes with the linear splicing of flanking exons during the canonical splicing machinery [25,26]. However, two reports have shown that depleting the splicing factors or components of U2 snRNPs increases the ratio of circRNAs to linear RNAs [27,28], indicating that the suppression or slowing of canonical pre-mRNA splicing machinery changes the steady-state production of linear transcripts to circular RNAs.

circRNA formation depends on two mechanisms. The first is base pairing between inverted repeat elements located in both the upstream and downstream introns [29]. In humans, 88% of these inverse-repeat elements are Alu repeats [10,30,31]. Double-stranded RNA (dsRNA)-specific adenosine deaminase (ADAR), which mediates adenosine to inosine editing in endogenous dsRNA, and DexH-Box helicase 9 (DHX9), which catalyzes the ATP-dependent unwinding of double-stranded RNA complexes, suppress the production of circRNAs that depend on base pairing between inverted repeats to prevent the looping of intron sequences [31,32]. In contrast, nuclear factor 90 (NF90) and 110 (NF110), both of which contain a nucleic acid-binding motif (double-stranded RNA-binding motif, dsRBM), promote the biogenesis of circRNAs by stabilizing the base pairing between inverted repeats. The second mechanism involves the dimerization of RNA-binding proteins (RBPs). Quaking (QKI), which belongs to the STAR family of KH domain-containing RBPs, promotes the biogenesis of circRNAs by stabilizing the base pairing between inverted repeats. The second mechanism involves the dimerization of RNA-binding proteins (RBPs). Quaking (QKI), which belongs to the STAR family of KH domain-containing RBPs, is associated with regions containing recognition elements within a single RNA, resulting in the stimulation of circRNA production [33]. FUS, also known as hnRNPP2, binds to intron regions proximal to the splice junctions involved in circRNA formation and affects the back-splicing reaction [34]. The other RBP of the heterogeneous nuclear ribonucleoprotein family, hnRNPL, binds preferentially to CA-repeat or CA-enriched RNA motifs in introns, resulting in enhanced circulation [35].

After processing in the nucleus, most exon-derived circRNAs are exported into the cytoplasm. RNAi screening assays have revealed that the DEAD box family proteins DDX39A and DDX39B transport circRNAs from the nucleus to the cytoplasm in a size-dependent manner [36].
3. Biological Roles of circRNAs

circRNAs can stably exist in various subcellular fractions, such as the nucleus, cytoplasm, ribosome, cytosol, and exosome, because their loop structures are not affected by the 3′-to-5′ RNA exonuclease RNase R. In general, circRNAs have independent functions from linear transcripts transcribed from the same host genes because of their longer half-lives. Increasing evidence has shown that circRNAs can associate with other regulatory factors, such as microRNAs (miRNAs) and RBPs, and participate in multiple processes, including splicing, transcription, chromatin modification, miRNA sponges, and protein decoys. Here, we summarize the biological functions of circRNAs, particularly with regard to cancer development.

3.1. miRNA Sponges

MiRNAs are post-transcriptional regulators that directly bind to mRNAs and inhibit translation or lead to mRNA degradation [37]. In recent years, increasing evidence has suggested that circRNA–miRNA–mRNA regulatory networks are important for exploring the pathogenesis and therapeutic strategies of cancer. One of the most widely investigated functions of circRNAs is to regulate posttranscriptional gene expression by acting as miRNA sponges. These circRNAs localize in the cytoplasm and contain multiple miRNA-binding sequences [10]. CiRS-7 (also termed cerebellar degeneration-related protein 1 antisense RNA (CDR1as)) was the first identified circRNA to harbor more than 70 binding sites for miR-7. MiR-7 is a tumor-suppressive miRNA involved in several pathophysiological pathways in hepatocellular carcinoma, breast cancer, and gastric cancer [38]. CiRS-7 prevents the degradation of miR-7-targeted mRNAs by functioning as a competing endogenous RNA [39].

To date, dozens of cancer-related circRNAs have been found to participate in the occupation of miRNA response elements. Hsa_circRNA_0088036 expression is upregulated in bladder cancer tissues and promotes cancer development by competing with miR-140-3p, resulting in the induction of FOXQ1 [40]. Fang et al. reported that circRNA phenylalanyl-tRNA synthetase subunit alpha (circFARSA) interacts with miR-330 and increases cell proliferation and invasion in bladder cancer tissues [41]. Hsa_circ_0000567 can act as a sponge for miR-421, which increases cell migration and invasion by directly binding to the 3′-UTR of TMEM100 mRNA in lung adenocarcinoma [42]. Downregulation of circ_0000567 accelerates the development of lung adenocarcinoma via the hsa_circ_0000567/miR-421/TMEM100 axis. CircSYPL1 expression is upregulated in patients with hepatocellular carcinoma; circSYPL1 sponges miR-506-3p to elevate EZH2 expression and induce tumorigenesis in hepatocellular carcinoma cells [43].

3.2. Epigenetic Regulation

Several studies have shown that circRNAs are involved in epigenetic regulation, including histone and chromatin modifications. circIMMP2L mediates the malignancy of esophageal squamous cell carcinoma (ESCC) by promoting the nuclear retention of CtBP1 [44]. In the nucleus, circIMMP2L mediates the interaction between CtBP1 and HDAC1 and induces the deacetylation of histone H3 in the promoter regions of E-cadherin and p21. CircMRPS35 recruits histone acetyltransferase KAT7 to the FOXO1 and FOXO3a promoter regions, leading to the acetylation of H4K5, which facilitates the activation of FOXO1/3a transcription [45]. FOXO1/3a affects the expression of downstream genes such as p21, Twist1, and E-cadherin, resulting in the suppression of cell proliferation and invasion.

3.3. Transcription and Alternative Splicing

Nuclear circRNAs can regulate gene expression by affecting transcription and alternative splicing, whereas cytoplasmic circRNAs function through interactions with miRNAs or proteins. ElciRNAs, mainly located in the nucleus, interact with U1 snRNP and promote the RNA Pol II-mediated transcription of their parental genes [17]. CircITGA7 downregulates colorectal cancer cell proliferation via facilitating the transcription of its host gene ITGA7 [46]. Ci-ankrd52, a circular intronic RNA generated from the ANKRD52 gene, is recruited to its transcription sites to promote RNA Pol II transcription [16].
The effects of circRNAs on pre-mRNA splicing have also been well characterized. CircRPAP2, a circRNA derived from the host gene RPAP2, is expressed in breast cancer tissues [47] and inhibits the proliferation and migration of breast cancer by competing with the association between the splicing factors SRSF1 and PTK2 pre-mRNA to modify the alternative splicing pattern of PTK2 mRNA. CircURI1 directly associates with hnRNPM to modulate the alternative splicing of a subset of genes involved in cell migration, resulting in the suppression of gastric cancer metastasis [48].

3.4. Protein Decoys

Several circRNAs harbor binding sites for RBPs and act as decoys to suppress protein function. For example, circMbl is derived from the splicing factor muscleblind (mbl) locus, which harbors multiple binding sites for the MBL protein [25]. CircMbl regulates MBL function by preventing its binding to its target RNAs. CircPABPN1 binds to Hu antigen R (HuR, also known as ELAV-like RNA-binding protein (ELAVL1)) to prevent the association of HuR with PABPN1 mRNA, resulting in the suppression of the effects of HuR on PABPN1 translation [49]. Circular antisense non-coding RNA in the INK4 locus (circANRIL) interacts with pescadillo homolog 1 (PES1) to disrupt pre-rRNA processing mediated by exonuclease in vascular smooth muscle cells [21]. Thus, circANRIL can control ribosome biogenesis to induce nucleolar stress and p53 activation, resulting in the stimulation of apoptosis, which is related to atherosclerosis pathology. Circ-transportin 3 (TNPO3) acts as a protein decoy for insulin-like growth factor 2 binding protein 3 (IGF2BP3) to interfere with the MYC/SNAIL axis, thereby decreasing the proliferation and metastasis of gastric cancer [50]. Chen et al. reported that circ_0000079 associates with Fragile X-Related 1 (FXR1) to interrupt the formation of the FXR1/protein kinase C, iota (PRKCI) complex, which mediates the inhibition of cell invasion and drug resistance in non-small cell lung cancer [51].

3.5. Translation into Peptides/Proteins

Although circRNAs have been categorized as non-coding RNAs, some circRNAs that harbor the open reading frame driven by internal ribosome entry sites are potentially translated into peptides or proteins [52,53]. Circ-ZNF609 exhibits internal ribosome entry site-dependent translation and functions in myoblast proliferation [54]. Zhang et al. reported that the circ-SNF2 histone linker PHD RING helicase (SHPRH) encodes a novel protein, SHPRH-146aa [55]. This truncated protein prevents the full-length SHPRH protein from degradation by the ubiquitin-proteasome and functions as a tumor suppressor in glioblastoma. CircMAPK14-175aa, a peptide of 175 amino acids encoded by the circMAPK14 gene, reduces the nuclear translocation of MAPK14 by competitively binding to MKK6 and blocking the progression of colorectal cancer [56]. Recent studies have shown that N6-methladenosine (m6A) RNA methylation can drive translation initiation in circRNAs [57]. circRNAs containing m6A are recognized by YTHDF3 and the translation initiation factor eIF4G2. Driven by m6A modification, the m6A reader protein IGF2BP1 promotes circMAP3K4 translation into circMAP3K4-455aa in hepatocellular carcinoma [58]. The expression of circMAP3K4-455aa prevents cisplatin-induced apoptosis and is associated with a worse prognosis in hepatocellular carcinoma patients.

Since most endogenous circRNAs are not associated with ribosomes and the potency of cap-independent translation may be inefficient, further studies are needed to reveal the coding potential of circRNAs.

4. Function of circRNAs in Esophageal Cancer

Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histological type, particularly in Japan. Despite advances in multidisciplinary treatment, the prognosis of patients with ESCC remains poor. Thus, further studies are needed to find specific diagnostic biomarkers and arise novel therapeutic targets. Recently, several circRNAs have been reported to be
differentially expressed between ESCC and adjacent normal tissues, indicating their key roles in ESCC development, progression, metastasis, and sensitivity to therapy.

4.1. Oncogenic circRNAs in Esophageal Cancer

Li et al. showed that ciRS-7 was significantly overexpressed in ESCC tissues [59]. The overexpression of ciRS-7 neutralized the suppressive effects of miR-7 on ESCC cell proliferation and migration both in vitro and in vivo. CiRS-7 sponges miR-7 to increase the expression of HOXB13 and then induces the phosphorylation of p65 in vitro. Overexpression of HOXB13 causes tumorigenesis in several cancer types, including prostate cancer [60]. The ciRS-7/miR-7/HOXB13/NF-κB/p65 pathway is aberrantly activated and induces malignant progression in ESCC [59]. CiRS-7 also increases the expression of KLF4, a transcription factor and a well-identified target of miR-7, and promotes the invasion of ESCC cells [61]. Sang et al. showed that ciRS-7 acts as a sponge for miR-876-5p and accelerates ESCC progression to enhance tumor antigen MAGE-A family expression. The online prediction database and luciferase reporter assay revealed that miR-876-5p directly targets MAGE-A family transcripts. Some of MAGE-A family genes have been shown to function as oncogenes in many cancer types, including ESCC [62,63]. CiRS-7 acts as a cancer-promoting circRNA to inhibit the binding of miR-876-5p on its downstream target tumor antigen MAGE-A family in ESCC. MiR-1299 has also been reported to be a target of ciRS-7. Meng et al. [64] showed that ciRS-7 markedly inhibits starvation- and rapamycin-induced autophagy in ESCC cells. Further research reveals that ciRS-7 acts as a sponge for miR-1299 and then activates its downstream AKT/mammalian target of the rapamycin (mTOR) signaling pathway via modulating epidermal growth factor receptor (EGFR) expression.

circCNOT6L (hsa_circ_0006168) consists of exons 2, 3, and 4 derived from CCR4-NOT transcription complex subunit 6 like (CNOT6L) on chromosome 4. Shi et al. showed that circCNOT6L is highly expressed in both ESCC tissues and cell lines [65]. High expression levels of circCNOT6L are associated with lymph node metastasis and tumor node metastasis (TNM) stage progression in patients with ESCC. circCNOT6L is mainly distributed in the cytoplasm and promotes ESCC proliferation, migration, and invasion through the miR-100/mTOR axis. Further studies showed that circCNOT6L targets miR-384 [66]. Knockdown of circCNOT6L enhanced miR-384 expression and inhibited tumor growth by inhibiting fibronectin 1 both in vitro and in vivo.

CircPDE3B (hsa_circ_0000277) comprises exons 2–4 derived from phosphodiesterase 3B (PDE3B). Zhou et al. showed significantly increased circPDE3B expression in ESCC tissues and cell lines [67]. High circPDE3B expression correlates with advanced TNM stage and poor prognosis in ESCC patients. Knockdown of circPDE3B suppresses proliferation, invasion, and epithelial–mesenchymal transition (EMT) phenotypes of ESCC cells in vitro and in vivo. CircPDE3B acts as a miR-4766-5p sponge and then inhibits the binding of miR-4766-5p on its target gene, laminin α1 (LAMA1). LAMA1 is frequently upregulated in multiple cancer types, such as colorectal carcinoma [68], melanoma [69], gastric cancer [70], and ESCC [71], and plays an important role in metastasis. Knockdown of circPDE3B decreases the expression levels of EMT-inducing factors, including MMP2/7/9, N-cadherin, Snail, Slug, and vimentin, and increases the expression of E-cadherin protein. Further studies have shown that circPDE3B also acts as a sponge for miR-873-5p, which targets Sry-related high-mobility group box 4 (SOX4) mRNA [72]. SOX4 is known to regulate the Wnt/β-catenin pathway in many cancers [73]. CircPDE3B knockdown inhibits the Wnt/β-catenin pathway by regulating the miR-873-5p/SOX4 axis and suppresses cell progression and cisplatin resistance in ESCC cells in vitro and in vivo.

4.2. Tumor Suppressive circRNAs in EC

CircFAT1 (hsa_circ_0001461) is formed by the back-splicing of exon 2 of the FAT1 gene and head-to-tail binding. Increasing evidence has shown that circFAT1 exerts tumor-suppressive effects in gastric cancer and colorectal cancer [74,75], and tumor-promoting
effects in osteosarcoma, papillary thyroid cancer, and hepatocellular carcinoma [76–79]. Takaki et al. [80] showed that circFAT1 expression levels are significantly lower in ESCC tissues than in non-tumorous tissues. In prognostic analysis, high circFAT1 expression is an independent factor for better recurrence-free survival and cancer-specific survival. CircFAT1 acts as a tumor suppressor by sponging miR-548g to suppress ESCC cell invasion and migration in vitro.

CircFAM120B (hsa_circ_0001666) is 2038 nucleotides long and originates from exons 2–4 of the \textit{FAM120B} gene. CircFAM120B is downregulated in both ESCC tissues and plasma from patients with ESCC [81]. Expression of circFAM120B is negatively related to tumor size, and patients with low circFAM120B expression have a poor prognosis. Exogenous circFAM120B inhibits the proliferation, invasion, and migration of ESCC cells. CircFAM120B acts as a sponge for miR-661, which targets the tumor-suppressor gene \textit{PPM1L}. CircFAM120B also binds to protein kinase R (PKR) and promotes its polyubiquitination and degradation. CircFAM120B negatively regulates the phosphorylation of p38 and the expression levels of N-cadherin and vimentin protein, whereas it positively regulates the protein level of E-cadherin. These results indicate that circFAM120B is a tumor-suppressive circRNA altering the miR-661/PPM1L axis and PKR/p38 MAPK/EMT pathway.

Meng et al. [82] found that ZEB1 inhibited the biogenesis of circDOCK5 (hsa_circ_0007618) by directly binding to the \textit{DOCK5} and \textit{EIF4A3} promoter. The expression levels of circDOCK5 are downregulated in ESCC tissues, and patients with low circDOCK5 expression levels have significantly shorter overall survival. CircDOCK5 increases the stability of miR-627-3p by functioning as a “reservoir”, and partially inhibits TGFB2 expression and TGF-\(\beta\) secretion, which further results in suppressed ZEB1 expression and EMT. These results indicate that ZEB1 downregulates circ-DOCK5 to facilitate metastasis by forming a positive feedback loop with TGF-\(\beta\) via miR-627-3p/TGFB2 signaling.

Since these studies were limited to a small number of cases, it is not yet clear whether these circRNAs act as oncogenes or tumor suppressors in ESCC. For example, Fan et al. [83] reported the tumor-suppressive function of ciRS-7, while ciRS-7 has been considered a tumor-promoting circRNA, as described above. They showed that the expression of ciRS-7 was significantly lower in ESCC tissues than in non-tumorous tissues. Multivariate Cox regression analysis revealed that low ciRS-7 expression was associated with significantly poorer prognosis in patients with ESCC. Further studies are needed to clarify the function and prognostic impact of each circRNA on ESCC.

4.3. \textit{circRNAs as Diagnostic and Prognostic Biomarkers for Esophageal Cancer}

Because of the high mortality rate associated with ESCC, early diagnosis and prognostic indicators are needed. Since circRNAs are abundantly expressed in cancer cells, they have the potential to be used as biomarkers for ESCC. Moreover, circRNAs are stable in human body fluids, including serum, plasma, urine, and microvesicles, indicating that they can be easily and repeatedly detected using noninvasive methods such as liquid biopsy [84]. Some studies have demonstrated circRNAs as potential biomarkers for the early diagnosis of ESCC and prediction of metastasis using clinical samples, including tissue and plasma from patients with ESCC (Table 1).
Table 1. Circular RNAs (circRNAs) as diagnostic and prognostic biomarkers for ESCC.

| circRNA     | CircBase ID    | Sample          | Dysregulation in ESCC | Clinicopathological Association                        | Potential Function            | AUC       | Sensitivity/ Specificity (%) | References |
|-------------|----------------|------------------|------------------------|--------------------------------------------------------|------------------------------|-----------|------------------------------|------------|
| circAAAS    | hsa_circ_0026611 | 69 serums up     | LNM \(^1\)             | Prognosis/Diagnosis                                     | 0.724                       | 0.800/0.529 | [85]                         |
| circALS2    | hsa_circ_0001093 | 40 tissues up     | LNM \(^1\), Tumor size | Prognosis                                              | [86]                         |           |                              |            |
| circATG5    | hsa_circ_0077536 | 125 tissues up    | TNM stage, LNM \(^1\)  | Prognosis                                              | [87]                         |           |                              |            |
| circCDK11A  | hsa_circ_0000005 | 125 tissues up    | Prognosis              | [87]                                                   |                              |           |                              |            |
| circUSP13   | hsa_circ_007541  | 125 tissues up    | Prognosis              | [87]                                                   |                              |           |                              |            |
| circCCT3    | hsa_circ_0014715 | 67 tissues up     | TNM stage, Differentiation, Vascular invasion | Diagnosis                                              | 0.722                       | 0.49/0.91 | [88]                         |
| circCDR1    | hsa_circ_0001946 | 123 tissues up    | Age                    | Prognosis                                              | [59]                         |           |                              |            |
| circCHD2    | hsa_circ_0000654 | 57 tissues up     | TNM stage, LNM \(^1\)  | Diagnosis                                              | [89]                         |           |                              |            |
| circCNOT6L  | hsa_circ_0006168 | 52 tissues up     | Tumor depth, LNM \(^1\) | Diagnosis                                              | [65]                         |           |                              |            |
| circCNOT6L  | hsa_circ_0006168 | 30 tissues up     | Diagnosis              | [66]                                                   |                              |           |                              |            |
| circFNDC3B  | hsa_circ_0006948 | 153 tissues up    | LNM \(^1\)             | Prognosis/Diagnosis                                     | 0.850                       | 0.74/0.88 | [90]                         |
| circGFPT1   | hsa_circ_0120816 | 36 tissues up     | Tumor depth, LNM \(^1\) | Diagnosis                                              | [91]                         |           |                              |            |
| circGSK3β   | hsa_circ_0007986 | 50 tissues up     | TNM stage, LNM \(^1\), LNM \(^1\) | Prognosis/Diagnosis                                     | 0.782                       | 0.86/0.58 | [92]                         |
| circHIPK3   | hsa_circ_0000284 | 32 tissues up     | LNM \(^1\), Tumor size, Differentiation | Diagnosis                                              | [93]                         |           |                              |            |
| circIMMP2L  | hsa_circ_0081964 | 54 tissues, 54 plasmas | Prognosis/Diagnosis                                              | 0.865                       | [44]                         |           |                              |            |
| CircLPAR3   | hsa_circ_0004390 | 10 tissues up     | TNM stage              | Prognosis                                              | [94]                         |           |                              |            |
| circNOX4    | hsa_circ_0023984 | 70 tissues up     | Prognosis              | [95]                                                   |                              |           |                              |            |
| circNTRK2   | hsa_circ_0087378 | 56 tissues up     | TNM stage, LNM \(^1\), LNM \(^1\) | Diagnosis                                              | [96]                         |           |                              |            |
| circOGDH    | hsa_circ_0003340 | 45 tissues up     | Prognosis              | [97]                                                   |                              |           |                              |            |
| circPDE3B   | hsa_circ_0002277 | 92 tissues up     | Prognosis              | [67]                                                   |                              |           |                              |            |
| circPDE3B   | hsa_circ_0002277 | 58 tissues up     | Prognosis              | [72]                                                   |                              |           |                              |            |
Table 1. Cont.

| circRNA      | CircBase ID      | Sample                  | Dysregulation in ESCC | Clinicopathological Association | Potential Function | AUC  | Sensitivity/ Specificity (%) | References |
|--------------|------------------|-------------------------|-----------------------|---------------------------------|-------------------|------|-----------------------------|------------|
| circPPFIA1   | hsa_circ_0000337 | 48 tissues, 25 tissues  | up                    | -                               | Diagnosis         |      |                             | [98]       |
| circPRRX1    | hsa_circ_0004370 | up                      | -                     | Tumor size                      | Diagnosis         |      |                             | [99]       |
| circRNF121   | hsa_circ_0023404 | 74 tissues, up          | -                     | Tumor size, TNM stage, LNM 1,   | Prognosis         |      |                             | [100]      |
| circSFMBT2   | hsa_circ_000211  | 39 tissues, up          | -                     | Tumor size, TNM stage, LNM 1,   | Diagnosis         |      |                             | [101]      |
| circSLC7A5   | hsa_circ_0040796 | 87 tissues, 24 tissues  | up                    | TNM stage                       | Prognosis/Diagnosis | 0.772 |                             | [102]      |
| circZDHHC5   | hsa_circ_0004997 | 39 tissues, up          | -                     | Tumor size, TNM stage, LNM 1,   | Diagnosis         |      |                             | [103]      |
| circZFR      | hsa_circ_0072088 | 83 tissues, up          | -                     | Tumor size, TNM stage, LNM 1,   | Diagnosis         |      |                             | [104]      |
| circATXN10   | hsa_circ_0008199 | 125 tissues, 10 tissues | down                  | LNM 1, Tumor size               | Prognosis         |      |                             | [87]       |
| circBMI1     | hsa_circ_0093335 | 125 tissues, 49 serums  | down                  | Histological type Tumor size,   | Diagnosis         | 0.726 | 0.96/0.47                    | [105]      |
| circCDR1     | hsa_circ_0001946 | 50 tissues, 50 plasmas  | down                  | Tumor size, LNM 1, Gender, CEA 2 | Prognosis/Diagnosis | 0.894 | 0.92/0.80                    | [83]       |
| circCNTNAP3  | hsa_circ_0087104 | 60 tissues, 130 tissues | down                  | -                               | Prognosis         |      |                             | [106]      |
| circDOCK5    | hsa_circ_0007618 | 100 tissues, 8 plasmas  | down                  | -                               | Prognosis         |      |                             | [82]       |
| circFAM120B  | hsa_circ_0001666 | 130 tissues, 8 plasmas  | down                  | Tumor size                      | Prognosis/Diagnosis |     |                             | [81]       |
| circFAT1     | hsa_circ_0001461 | 51 tissues              | down                  | Age                             | Prognosis         |      |                             | [80]       |
| circKRT19    | hsa_circ_0043603 | 50 tissues, 50 plasmas  | down                  | TNM stage, CEA 2, TNM stage,    | Diagnosis         | 0.836 | 0.64/0.92                    | [83]       |
| circNTRK2    | hsa_circ_0087378 | 50 tissues              | down                  | TNM stage, LNM 1, Tumor size    | Prognosis         |      |                             | [107]      |
| circSMAD7    | hsa_circ_0000848 | 36 tissues, 32 plasmas  | down                  | TNM stage, LNM 1                | Diagnosis         | 0.859 | -                            | [108]      |

1 LNM: lymph node metastasis, 2 CEA: carcinoembryonic antigen.
CircFNDC3B (hsa_circ_0006948), derived from exons 2, 3, and 4 of fibronectin type III domain-containing protein 3B (FNDC3B), is upregulated in ESCC tissues and cell lines [90]. Fluorescence in situ hybridization showed that circFNDC3B was preferentially expressed in the cytoplasm. High circFNDC3B expression was positively related to lymph node metastasis but not to other clinicopathological features such as age, T stage, sex, blood type, tumor location, and differentiation. Kaplan–Meier survival curves have shown that patients with high circFNDC3B expression had a significantly shorter overall survival [90]. The detection of circFNDC3B in ESCC tissues exhibited relatively good diagnostic performance with an area under the ROC curve (AUC), sensitivity, and specificity in EC tissues of 0.85, 0.74%, and 0.88%, respectively [90].

CircGSK3β (hsa_circ_0007986, also named circRNA_103443) is a back-splice variant of exons 3, 4, and 5 of the Glycogen synthase kinase-3β (GSK3β) gene located at 3q22.1. GSK3β is an important mediator of the Wnt signaling pathway and leads to the development and progression of many cancer types [109]. The expression of circGSK3β is frequently higher in ESCC tissues than in adjacent normal tissues [92]. Patients with high circGSK3β expression levels showed a worse TNM stage and lymph node metastasis. Kaplan–Meier survival curves have shown that patients with high circGSK3β expression had a significantly shorter metastasis-free survival (hazard ratio = 2.93) and overall survival (hazard ratio = 6.04). Compared to those in the healthy control group and with benign lesions, the abundance of circGSK3β in the plasma was significantly increased in patients with ESCC. The plasma levels of circGSK3β had relatively good diagnostic performance in ESCC tissues, with AUC, sensitivity, and specificity values of 0.78, 0.86%, and 0.58%, respectively. When plasma levels of circGSK3β were combined with a commonly used diagnostic marker, carcinoembryonic antigen (CEA), the AUC and specificity increased to 0.800 and 67.4%, respectively [92]. Moreover, the combination of circGSK3β with CEA markedly increased the sensitivity to 87.5% in the early stages of ESCC. Patients with recurrence/metastasis 10 months after surgery showed higher expression levels of circGSK3β compared to patients without recurrence/metastasis, indicating that quantification of plasma circGSK3β level is valuable to predict recurrence/metastasis of ESCC [92].

CircIMMP2L (hsa_circ_0081964) is derived from exons 2–4 of the Inner Mitochondrial Membrane Peptidase Subunit 2 (IMMP2L) gene. circIMMP2L has significantly higher expression in ESCC tissues from patients with an advanced TNM stage and lymph node metastasis [44]. The expression of plasma circIMMP2L in patients with advanced-stage ESCC or lymph node metastasis was significantly upregulated compared to that in healthy individuals. Quantification of circIMMP2L in plasma exhibited a relatively good diagnostic performance for the detection of lymph node metastasis, with an AUC of 0.865 [44].

Fan et al. [83] profiled circRNAs both in ESCC and non-tumor tissues and determined six circRNAs (hsa_circ_0062459, hsa_circ_0076535, hsa_circ_0072215, hsa_circ_0042261, hsa_circ_0001946, and hsa_circ_0043603) as the differentially expressed circRNAs. Among them, hsa_circ_0062459, hsa_circ_0001946, and hsa_circ_0043603 were detectable in the plasma. Furthermore, hsa_circ_0001946 and hsa_circ_0043603 could be useful for diagnostic biomarkers. The AUC, sensitivity, and specificity of hsa_circ_0001946 were 0.894, 92%, and 80%, respectively, while those of hsa_circ_0043603 were 0.836, 64%, and 92%, respectively. Hsa_circ_0001946 also predicted recurrence, overall survival, and disease-free survival in frozen and formalin-fixed, paraffin-embedded tissues.

A model based on the expression values of several circRNAs can improve the diagnostic and prognostic accuracy of ESCC. Wang et al. [87] established a prognostic risk model composed of circUSP13 (hsa_circ_0007541), circCDK11A (hsa_circ_0000005), circATG5 (hsa_circ_0077536), and circATXN10 (has_circ_0008199). The risk score of the selected circRNA signature demonstrated good performance in survival prediction and could be used as a sensitive prognostic biomarker in patients with ESCC, with an AUC of 0.839 [87].

Although the potential of circRNAs as ESCC biomarkers is becoming clear, their true value requires further validation in a larger cohort of clinical samples. Furthermore, in the
absence of suitable biomarkers with high specificity and sensitivity at the same time, new diagnostic models must be established.

4.4. circRNAs as Potential Therapeutic Targets for Esophageal Cancer

The regulatory role of circRNAs in cancer is gradually becoming clearer, and circRNAs can be developed as effective therapeutic targets in the future.

Several circRNAs have been reported as predictors of the response to radiation therapy and chemotherapy (Table 2). Hsa_circ_0014879, derived from DDB1 and CUL4 associated factor 8 (DCAF8), is highly expressed in the radioresistant ESCC cell line KYSE-150R [110]. Hsa_circ_0014879 is involved in ESCC radioresistance via the miR-217/Wnt3 [110] and miR-519-3p/CDC25A pathways [111]. In contrast, hsa_circ_0000518 derived from ribonuclease P RNA component H1 (RPPH1), also called circRNA_000167, is downregulated in KYSE-150R cells, suggesting that hsa_circ_0000518 enhances sensitivity to radiation therapy [112]. Cisplatin, fluorouracil, and paclitaxel are clinically used for the treatment of ESCC. CircDOCK1 (hsa_circ_0007142), derived from Dedicator of cytokinesis 1 (DOCK1), is upregulated in cisplatin-resistant ESCC tissues and cells [113]. Uprregulated circDOCK1 is involved in cisplatin resistance by upregulating LIM and SH3 protein 1 (LASP1) by miR-494-3p sponging. circCNOT6L is upregulated in paclitaxel-resistant ESCC cells [114]. circCNOT6L promotes paclitaxel resistance in ESCC by regulating the miR-194-5p/jumonji domain containing 1C (JMJD1C) axis, suggesting that circCNOT6L may be a therapeutic target for ESCC chemotherapy.

Table 2. circRNAs as biomarker for radio- and chemo-sensitivity in ESCC.

| circRNA                  | CircBase ID       | Biological Function | Sample       | References |
|--------------------------|-------------------|---------------------|--------------|------------|
| **circRNAs as Radiosensitive or Radioresistance Biomarkers for EC** |                   |                     |              |            |
| circDCAF8                | hsa_circ_0014879  | Radioresistance     | KYSE150      | [110]      |
| circLIN52                | hsa_circ_0000554  | Radioresistance     | KYSE150      | [112]      |
| circRPPH1                | hsa_circ_0000518  | Radiosensitive      | KYSE150      | [112]      |
| **circRNAs as Chemoresistance Biomarkers for EC** |                   |                     |              |            |
| circTMX4                 | hsa_circ_0001131  | Cisplatin resistance| KYSE30, ECA109 ESCC tissues, TE1, ECA109 | [115]      |
| circDOPEY2               | hsa_circ_0008078  | Cisplatin resistance| KYSE410      | [113]      |
| circDOCK1                | hsa_circ_0007142  | Cisplatin resistance| KYSE410      | [113]      |
| circPDE3B                | hsa_circ_0000277  | Cisplatin resistance| KYSE410      | [72]       |
| circPPFIA1               | has_circ_0000337  | Cisplatin resistance| KYSE410      | [117]      |
| circCNOT6L               | has_circ_0006168  | Paclitaxel resistance| KYSE410 KYSE150, ECA109 | [114]      |

Rapidly increasing evidence has revealed that exosomes from resistant cells can render chemosensitive cells resistant to drugs. The structure of exosomes blocks RNA degradation and guarantees an efficient concentration of circRNAs. The size and membrane structure of exosomes also promote the absorption and fusion of cancer cells. Recently, Zang et al. [117] reported that exosome-mediated circPPFIA1 could induce chemoresistance in ESCC cells. CircPPFIA1 (has_circ_0000337), derived from PTPRF interacting protein alpha 1 (PPFIA1), promotes cisplatin resistance in ESCC cells by modulating the miR-377-3p/JAK2 axis. CircPPFIA1-containing exosomes secreted from cisplatin-resistant esophageal cancer cells can promote chemoresistance, cell growth, and metastasis in cisplatin-sensitive ESCC cells both in vitro and in vivo.
Although specific therapeutic developments directly targeting circRNAs have not yet been reported, the use of synthetic circRNA sponges may be an effective strategy. Synthetic circRNAs containing miR-21 binding sites have been shown to cause a loss of miRNA function in vitro, suggesting that synthetic circRNA sponges have potential for the treatment of cancer patients [118].

5. Conclusions

To date, dozens of studies have determined that circRNAs are a large class of non-coding RNAs with a cell type-specific and tissue-specific expression that act as crucial regulators for gene expression. However, little is known regarding the functions and molecular mechanisms involved in cancer development and metastasis. The most commonly used markers are not specific or sensitive enough to be used as early diagnosis and prognostic indicators. The characteristics of circRNAs, such as their stability, abundance, and widespread distribution, make them a promising biomarker for the clinical diagnosis and prognosis of cancer. As reported for various miRNAs, individual circRNAs are unlikely to be sensitive and specific to all types of cancers, and one specific circRNA may not be sufficient for cancer diagnosis or prognosis prediction. Therefore, a combination of cancer-related circRNA panels could be useful as biomarkers for future clinical diagnoses. circRNAs also have great potential as therapeutic targets. A new and effective therapeutic approach may be to modulate the cellular function of endogenous circRNAs or to introduce synthetic circRNAs into cancer cells. Although specific therapeutic developments directly targeting circRNAs have not yet been established, further research will serve as a basis for clinical use.

Author Contributions: Conceptualization, K.S., Y.K. and K.M.; writing—original draft preparation, K.S., Y.K. and K.M.; writing—review and editing, D.I. and K.M.; All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by JSPS KAKENHI (grant number JP21K07971) as a Grant-in-Aid for Scientific Research (C) (to K.M.). There is no funding agency for this work.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Sanger, H.L.; Klotz, G.; Riesner, D.; Gross, H.J.; Kleinschmidt, A.K. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl. Acad. Sci. USA 1976, 73, 3852–3856. [PubMed]
2. Hsu, M.T.; Coca-Prados, M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 1979, 280, 339–340. [PubMed]
3. Nigro, J.M.; Cho, K.R.; Fearon, E.R.; Kern, S.E.; Ruppert, J.M.; Oliner, J.D.; Kinzler, K.W.; Vogelstein, B. Scrambled exons. Cell 1991, 64, 607–613. [PubMed]
4. Cocquerelle, C.; Daubersies, P.; Majerus, M.A.; Kerckaert, J.P.; Bailleul, B. Splicing with inverted order of exons occurs proximal to large introns. EMBO J. 1992, 11, 1095–1098.
5. Cocquerelle, C.; Mascrez, B.; Hetuin, D.; Bailleul, B. Mis-splicing yields circular RNA molecules. FASEB J. 1993, 7, 155–160.
6. Capel, B.; Swain, A.; Nicolis, S.; Hacker, A.; Walter, M.; Koopman, P.; Goodfellow, P.; Lovell-Badge, R. Circular transcripts of the testis-determining gene Sry in adult mouse testis. Cell 1993, 73, 1019–1030.
7. Braun, S.; Domdey, H.; Wiebauer, K. Inverse splicing of a discontinuous pre-mRNA intron generates a circular exon in a HeLa cell nuclear extract. Nucleic Acids Res. 1996, 24, 4152–4157. [CrossRef]
8. Pasman, Z.; Been, M.D.; Garcia-Blanco, M.A. Exon circularization in mammalian nuclear extracts. RNA 1996, 2, 603–610.
9. Salzman, J.; Gawad, C.; Wang, P.L.; Lacayo, N.; Brown, P.O. Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS ONE 2012, 7, e30733. [CrossRef]
10. Jeck, W.R.; Sorrentino, J.A.; Wang, K.; Slevin, M.K.; Burd, C.E.; Liu, J.; Marzluff, W.F.; Sharpless, N.E. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA 2013, 19, 141–157.
11. Memczak, S.; Jens, M.; Elefsinioti, A.; Torti, F.; Krueger, J.; Rybak, A.; Maier, L.; Mackowiak, S.D.; Gregersen, L.H.; Munschauer, M.; et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature 2013, 495, 333–338. [CrossRef] [PubMed]
12. Westholm, J.O.; Miura, P.; Olson, S.; Shenker, S.; Joseph, B.; Sanfilippo, P.; Celniker, S.E.; Graveley, B.R.; Lai, E.C. Genome-wide analysis of drosophila circular RNAs reveals their structural and sequence properties and age-dependent neural accumulation. *Cell Rep.* 2014, 9, 1966–1980. [CrossRef] [PubMed]

13. Rybak-Wolf, A.; Stottmeister, C.; Glazar, P.; Jens, M.; Pino, N.; Giusti, S.; Hanan, M.; Behm, M.; Bartok, O.; Ashwal-Fluss, R.; et al. Circular RNAs in the Mammalian Brain Are Highly Abundant, Conserved, and Dynamically Expressed. *Mol. Cell* 2015, 58, 870–885. [CrossRef] [PubMed]

14. Gruner, H.; Cortes-Lopez, M.; Cooper, D.A.; Bauer, M.; Miura, P. circRNA accumulation in the aging mouse brain. *Sci. Rep.* 2016, 6, 38907. [CrossRef] [PubMed]

15. Guo, J.U.; Agarwal, V.; Guo, H.; Bartel, D.P. Expanded identification and characterization of mammalian circular RNAs. *Genome Biol.* 2014, 15, 409. [CrossRef]

16. Zhang, Y.; Zhang, X.O.; Chen, T.; Xiang, J.F.; Yin, Q.F.; Xing, Y.H.; Zhu, S.; Yang, L.; Chen, L.L. Circular intronic long noncoding RNAs. *Mol. Cell* 2013, 51, 792–806. [CrossRef]

17. Li, Z.; Huang, C.; Bao, C.; Chen, L.; Lin, M.; Wang, X.; Zhong, G.; Yu, B.; Hu, W.; Dai, L.; et al. Exon-intron circular RNAs regulate transcription in the nucleus. *Nat. Struct. Mol. Biol.* 2015, 22, 256–264. [CrossRef]

18. Bachmayr-Heyda, A.; Reinr, A.T.; Auer, K.; Sukhbaatar, N.; Aust, S.; Bachleitner-Hofmann, T.; Mesteri, I.; Grunt, T.W.; Zeillinger, R.; Pilis, D. Correlation of circular RNA abundance with proliferation–exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. *Sci. Rep.* 2015, 5, 8057. [CrossRef]

19. Xu, H.; Guo, S.; Li, W.; Yu, P. The circular RNA Cdr1as, via miR-7 and its targets, regulates insulin transcription and secretion in islet cells. *Sci. Rep.* 2015, 5, 12453. [CrossRef]

20. Zhao, Y.H.; Alexandrov, P.N.; Jaber, V.; Lukiw, W.J. Deficiency in the Ubiquitin Conjugating Enzyme UBE2A in Alzheimer’s Disease (AD) is Linked to Deficits in a Natural Circular miRNA-7 Sponge (circRNA; cIR-7). *Genes* 2016, 7, 116. [CrossRef]

21. Holdt, L.M.; Stahringer, A.; Sass, K.; Pichler, G.; Kulak, N.A.; Wilfert, W.; Kohlmaier, A.; Herbst, A.; Northoff, B.H.; Nicolaou, A.; et al. Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans. *Nat. Commun.* 2016, 7, 12429. [CrossRef]

22. Li, H.; Li, K.; Lai, W.; Li, X.; Wang, H.; Yang, J.; Chu, S.; Wang, H.; Kang, C.; Qiu, Y. Comprehensive circular RNA profiles in plasma reveals that circular RNAs can be used as novel biomarkers for systemic lupus erythematosus. *Clin. Chim. Acta* 2018, 480, 17–25. [CrossRef] [PubMed]

23. Rajappa, A.; Banerjee, S.; Sharma, V.; Khandelia, P. Circular RNAs: Emerging Role in Cancer Diagnostics and Therapeutics. *Front. Mol. Biosci.* 2020, 7, 577938. [CrossRef]

24. Salzman, J.; Chen, R.E.; Olsen, M.N.; Wang, P.L.; Brown, P.O. Cell-type specific features of circular RNA expression. *PLoS Genet.* 2013, 9, e1003777. [CrossRef]

25. Ashwal-Fluss, R.; Meyer, M.; Pamudurti, N.R.; Ivanov, A.; Bartok, O.; Hanan, M.; Evantal, N.; Memczak, S.; Rajewsky, N.; Kadener, S. circRNA biogenesis competes with pre-mRNA splicing. *Mol. Cell* 2014, 56, 55–66. [CrossRef] [PubMed]

26. Starka, S.; Jost, I.; Rossbach, O.; Schneider, T.; Schreiner, S.; Hung, L.H.; Bindereif, A. Exxon circuclearization requires canonical splice signals. *Cell Rep.* 2015, 10, 103–111. [CrossRef] [PubMed]

27. Kramer, M.C.; Liang, D.; Tatomer, D.C.; Gold, B.; March, Z.M.; Cherry, S.; Wilusz, J.E. Combinatorial control of Drosohphila circular RNA expression by intrinsic repeats, hnRNPs, and SR proteins. *Genes Dev.* 2015, 29, 2168–2182. [CrossRef] [PubMed]

28. Liang, D.; Tatomer, D.C.; Luo, Z.; Wu, H.; Yang, L.; Chen, L.L.; Cherry, S.; Wilusz, J.E. The Output of Protein-Coding Genes Shifts to Circular RNAs When the Pre-mRNA Processing Machinery Is Limiting. *Mol. Cell* 2017, 68, 940–954.e943. [CrossRef]

29. Dubin, R.A.; Kazmi, M.A.; Ostre, H. Inverted repeats are necessary for circularization of the mouse testis Sry transcript. *Gene* 1995, 167, 245–248. [CrossRef]

30. Zhang, X.O.; Wang, H.B.; Zhang, Y.; Lu, X.; Chen, L.L.; Yang, L. Complementary sequence-mediated exon circularization. *Cell* 2014, 159, 134–147. [CrossRef]

31. Ivanov, A.; Memczak, S.; Wyler, E.; Torti, F.; Porath, H.T.; Orejuela, M.R.; Piechotta, M.; Levanon, E.Y.; Landthaler, M.; Kadener, S.; et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. *Cell Rep.* 2015, 10, 170–177. [CrossRef] [PubMed]

32. Aktas, T.; Avsar Ilik, I.; Maticzka, D.; Bhardwaj, V.; Pessoa Rodrigues, C.; Mittler, G.; Manke, T.; Backofen, R.; Akhtar, A. DNX9 suppresses RNA processing defects originating from the Alu invasion of the human genome. *Nature* 2017, 544, 115–119. [CrossRef] [PubMed]

33. Conn, S.J.; Pillman, K.A.; Toubia, J.; Conn, VM., Salandinis, M.; Phillips, C.A.; Roslan, S.; Schreiber, A.W.; Gregory, P.A.; Goodall, G.J. The RNA binding protein quaking regulates formation of circRNAs. *Cell* 2015, 160, 1125–1134. [CrossRef] [PubMed]

34. Errichelli, L.; Dini Modigliani, S.; Lanepe, P.; Colantonio, A.; Legnini, I.; Capuoto, D.; Rosa, A.; De Santis, R.; Scarfo, R.; Peruzzi, G.; et al. FUS affects circular RNA expression in murine embryonic stem cell-derived motor neurons. *Nat. Commun.* 2017, 8, 14741. [CrossRef] [PubMed]

35. Fei, T.; Chen, Y.; Xiao, T.; Li, W.; Cato, L.; Zhang, P.; Cotter, M.B.; Bowden, M.; Lis, R.T.; Zhao, S.G.; et al. Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. *Proc. Natl. Acad. Sci. USA* 2017, 114, E5207–E5215. [CrossRef]

36. Huang, C.; Liang, D.; Tatomer, D.C.; Wilusz, J.E. A length-dependent evolutionarily conserved pathway controls nuclear export of circular RNAs. *Genes Dev.* 2018, 32, 639–644. [CrossRef] [PubMed]
37. Ambros, V. The functions of animal microRNAs. *Nature* **2004**, *431*, 350–355. [CrossRef]

38. Kalinowski, F.C.; Brown, R.A.M.; Ganda, C.; Giles, K.M.; Epis, M.R.; Horsham, J.; Leedman, P.J. microRNA-7: A tumor suppressor miRNA with therapeutic potential. *Int. J. Biochem. Cell Biol.* **2014**, *54*, 312–317. [CrossRef]

39. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bramsen, J.B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. *Nature* **2013**, *495*, 384–388. [CrossRef]

40. Yang, J.; Qi, M.; Fei, X.; Wang, X.; Wang, K. Hsa_circRNA_0088036 acts as a ceRNA to promote bladder cancer progression by sponging miR-140-3p. *Cell Death Dis.* **2022**, *13*, 322. [CrossRef]

41. Fang, C.; Huang, X.; Dai, J.; He, W.; Xu, L.; Sun, F. The circular RNA circFARSA sponges microRNA-330-5p in tumor cells with bladder cancer phenotype. *BMC Cancer* **2022**, *22*, 373. [CrossRef] [PubMed]

42. Hong, Y.; Si, J.; Xiao, B.; Xiong, Y.; Dai, C.; Yang, Y.; Li, S.; Ma, Y. circ_000567/miR-421/TMEM100 Axis Promotes the Migration and Invasion of Lung Adenocarcinoma and Is Associated with Prognosis. *J. Cancer* **2022**, *13*, 1540–1552. [CrossRef] [PubMed]

43. Lei, D.; Wang, T. circSYPL1 Promotes the Proliferation and Metastasis of Hepatocellular Carcinoma via the Upregulation of EZH2 Expression by Competing with hsa-miR-506-3p. *J. Oncol.* **2022**, *2022*, 2659563. [CrossRef] [PubMed]

44. Liang, Y.; Mao, Q.; Wang, L.; Xia, W.; Chen, B.; Wang, H.; Li, R.; Xu, L.; Jiang, F.; Dong, G. circMIMP2L promotes esophageal squamous cell carcinoma malignant progression via CtbP1 nuclear retention dependent epigenetic modification. *Clin. Transl. Med.* **2021**, *11*, e519. [CrossRef]

45. Jie, M.; Wu, Y.; Gao, M.; Li, X.; Liu, C.; Ouyang, Q.; Tang, Q.; Shan, C.; Lv, Y.; Zhang, K.; et al. CircMRPS35 suppresses gastric cancer progression via recruiting KAT7 to govern histone modification. *Mol. Cancer* **2020**, *19*, 36. [CrossRef]

46. Li, X.; Wang, J.; Zhang, C.; Lin, C.; Zhang, J.; Zhang, W.; Zhang, W.; Yu, L.; Zheng, L.; Li, X. Circular RNA circITGA7 inhibits colorectal cancer growth and metastasis by modulating the Ras pathway and upregulating transcription of its host gene ITGA7. *J. Pathol.* **2018**, *246*, 160–179. [CrossRef]

47. Yu, Y.; Fang, L. CircRPA2 regulates the alternative splicing of PTK2 by binding to SRSF1 in breast cancer. *Cell Death Discov.* **2022**, *8*, 152. [CrossRef]

48. Wang, X.; Li, J.; Bian, X.; Wu, C.; Hua, J.; Chang, S.; Yu, T.; Li, H.; Li, Y.; Hu, S.; et al. CircURR1 interacts with hnRNPM to inhibit metastasis by modulating alternative splicing in gastric cancer. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2012881118. [CrossRef]

49. Abdelmohsen, K.; Panda, A.C.; Munk, R.; Grammatikakis, I.; Dudekula, D.B.; De, S.; Kim, J.; Noh, J.H.; Kim, K.M.; Martindale, J.L.; et al. Identification of HuR target circular RNAs uncovers suppression of PAPBP1 translation by CircPAPBP1. *RNA Biol.* **2017**, *14*, 361–369. [CrossRef]

50. Yu, T.; Ran, L.; Zhao, H.; Yin, P.; Li, W.; Lin, J.; Mao, H.; Cai, D.; Ma, Q.; Pan, X.; et al. Circular RNA circ-TNPO3 suppresses metastasis of GC by acting as a protein decoy for IGF2BP3 to regulate the expression of MYC and SNAI1. *Mol. Ther. Nucleic Acids* **2021**, *26*, 649–664. [CrossRef]

51. Chen, C.; Zhang, M.; Zhang, Y. Circ_0000079 Decays the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCK1 Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC. *Cell Transplant.* **2020**, *29*, 963689720961070. [CrossRef] [PubMed]

52. Chen, C.Y.; Sarnow, P. Initiation of Protein Synthesis by the Eukaryotic Translational Apparatus on Circular RNAs. *Science* **1995**, *268*, 415–417. [CrossRef] [PubMed]

53. Chen, C.-K.; Cheng, R.; Demeter, J.; Chen, J.; Weingarten-Gabbay, S.; Jiang, L.; Snyder, M.P.; Weissman, J.S.; Segal, E.; Jackson, P.K.; et al. Structured elements drive extensive circular RNA translation. *Nature* **2017**, *543*, 361–369. [CrossRef] [PubMed]

54. Zhang, M.; Huang, N.; Yang, X.; Luo, J.; Yan, S.; Xiao, F.; Chen, W.; Gao, X.; Zhao, K.; Zhou, H.; et al. A novel protein encoded by N6-methyladenosine modified circMAP3K4 prevents apoptosis in hepatocellular carcinoma. *Int. J. Biochem. Cell Biol.* **2021**, *132*, 105667. [CrossRef] [PubMed]

55. Yang, Y.; Fan, X.; Mao, M.; Song, X.; Wu, P.; Zhang, Y.; Jin, Y.; Yang, Y.; Chen, L.-L.; Wang, Y.; et al. Extensive translation of circular RNAs driven by N6-methyladenosine. *Cell Res.* **2017**, *27*, 626–641. [CrossRef]

56. Duan, J.-L.; Chen, W.; Xie, J.-J.; Zhang, M.-L.; Nie, R.-C.; Liang, H.; Mei, J.; Han, K.; Xiang, Z.-C.; Wang, F.-W.; et al. A novel peptide encoded by N6-methyladenosine modified circMAPK3K4 prevents apoptosis in hepatocellular carcinoma. *Mol. Cancer* **2022**, *21*, 93. [CrossRef]

57. Martindale, J.L.; et al. Identification of HuR target circular RNAs uncovers suppression of PABPN1 translation by CircPAPBP1. *RNA Biol.* **2021**, *18*, 93. [CrossRef] [PubMed]
63. Sang, M.; Gu, L.; Liu, F.; Lian, Y.; Yin, D.; Fan, X.; Ding, C.; Huang, W.; Liu, S.; Shan, B. Prognostic Significance of MAGE-A11 in Esophageal Squamous Cell Carcinoma and Identification of Related Genes Based on DNA Microarray. Arch. Med. Res. 2016, 47, 151–161. [CrossRef]

64. Meng, L.; Liu, S.; Ding, P.; Chang, S.; Sang, M. Circular RNA circRS-7 inhibits autophagy of ESCC cells by functioning as miR-1299 sponge to target EGFR signaling. J. Cell. Biochem. 2020, 121, 1039–1049. [CrossRef] [PubMed]

65. Shi, Y.; Guo, Z.; Fang, N.; Jiang, W.; Fan, Y.; He, Y.; Ma, Z.; Chen, Y. hsa_circ_0006168 sponges miR-100 and regulates mTOR to promote the proliferation, migration and invasion of esophageal squamous cell carcinoma. Biomed. Pharmacother. 2019, 117, 109151. [CrossRef] [PubMed]

66. Zhang, Y.; Tang, Q.; Huang, X.M.; Liao, D.Z. Circular RNA circCNOT6L regulates cell development through modulating miR-384/FN1 axis in esophageal squamous cell carcinoma. Eur. Rev. Med. Pharmacol. Sci. 2020, 24, 3674–3685. [CrossRef]

67. Zhou, P.L.; Wu, Z.; Zhang, W.; Xu, M.; Ren, J.; Zhang, Q.; Sun, Z.; Han, X. Circular RNA hsa_circ_0002277 sequesters miR-4766-5p to upregulate LAMA1 and promote esophageal carcinoma progression. Cell Death Dis. 2021, 12, 676. [CrossRef]

68. Mammadova-Bach, E.; Rupp, T.; Spences, C.; Jivkov, I.; Shankaranarayanan, P.; Klein, A.; Pisarsky, L.; Mechine-Neuville, A.; Cremel, G.; Kedinger, M.; et al. Laminin alpha1 vesicles VEGRF functions in the ecosystem of colorectal carcinoma. Biol. Cell 2018, 110, 178–195. [CrossRef]

69. Chen, J.; Wu, F.; Shi, Y.; Yang, D.; Xu, M.; Lai, Y.; Liu, Y. Identification of key candidate genes involved in melanoma metastasis. Mol. Med. Rep. 2019, 20, 903–914. [CrossRef]

70. Caldeira, J.; Figueiredo, J.; Bras-Pereira, C.; Carneiro, P.; Moreira, A.M.; Pinto, M.T.; Relvas, J.B.; Carneiro, F.; Barbosa, M.; Casares, F.; et al. E-cadherin-defective gastric cancer cells depend on Laminin to survive and invade. Hum. Mol. Genet. 2015, 24, 5891–5900. [CrossRef]

71. Meng, X.; Chen, X.; Lu, P.; Ma, W.; Yue, D.; Song, L.; Fan, Q. MicroRNA-202 inhibits tumor progression by targeting LAMA1 in esophageal squamous cell carcinoma. Biochim. Biophys. Res. Commun. 2016, 473, 821–827. [CrossRef] [PubMed]

72. Cheng, J.; Zhang, R.; Yan, M.; Li, Y. Circular RNA hsa_circ_0002277 promotes tumor progression and DDP resistance in esophageal squamous cell carcinoma. BMC Cancer 2022, 22, 238. [CrossRef] [PubMed]

73. Grimm, D.; Bauer, J.; Wise, P.; Krüger, M.; Simonsen, U.; Wehland, M.; Münzker, M.; Corydon, T.J. The role of SOX family members in solid tumours and metastasis. Semin. Cancer Biol. 2020, 67, 122–153. [CrossRef] [PubMed]

74. Fang, J.; Hong, H.; Xue, X.; Zhu, X.; Liang, L.; Qin, M.; Liang, H.; Gao, L. A novel circular RNA, circFAT1(e2), inhibits gastric cancer progression by targeting miR-546g in the cytoplasm and interacting with YBX1 in the nucleus. Cancer Lett. 2019, 442, 222–232. [CrossRef] [PubMed]

75. Hu, B.; Xian, Z.; Zou, Q.; Zhang, D.; Su, D.; Yao, J.; Ren, D. CircFAT1 Suppresses Colorectal Cancer Development Through Regulating miR-520b/UHRF1 Axis or miR-302c-3p/UHRF1 Axis. Cancer Biother. Radiopharm. 2021, 36, 45–57. [CrossRef]

76. Liu, G.; Huang, K.; Jie, Z.; Wu, Y.; Chen, J.; Chen, Z.; Fang, X.; Shen, S. CircFAT1 sponges miR-375 to promote the expression of Yes-associated protein 1 in osteosarcoma cells. Mol. Cancer 2018, 17, 170. [CrossRef]

77. Gu, H.; Cheng, X.; Xu, J.; Zhou, K.; Bian, C.; Chen, G.; Yin, X. Circular RNA circFAT1(e2) Promotes Osteosarcoma Progression and Metastasis by Sponging miR-181b and Regulating HK2 Expression. Biomed. Res. Int. 2020, 2020, 3589871. [CrossRef]

78. Liu, J.; Li, H.; Wei, C.; Ding, L.; Lu, J.; Pan, G.; Mao, A. circFAT1(e2) Promotes Papillary Thyroid Cancer Proliferation, Migration, and Invasion via the miRNA-873/ZEB1 Axis. Comput Math. Methods Med. 2020, 2019, 1459956. [CrossRef]

79. Wei, H.; Yan, S.; Hui, Y.; Liu, Y.; Guo, H.; Li, Q.; Li, J.; Chang, Z. CircFAT1 promotes hepatocellular carcinoma progression via miR-30a-5p/REEP3 pathway. J. Cell Mol. Med. 2020, 24, 14561–14570. [CrossRef]

80. Takaki, W.; Konishi, H.; Shoda, K.; Arita, T.; Kataoka, S.; Shibamoto, J.; Furuke, H.; Takabatake, K.; Shimizu, H.; Komatsu, S.; et al. Significance of CircFAT1 as a Prognostic Factor and Tumor Suppressor for Esophageal Squamous Cell Carcinoma. Ann. Surg. Oncol. 2021, 28, 8508–8518. [CrossRef]

81. Song, H.; Tian, D.; Sun, J.; Mao, X.; Kong, W.; Xu, D.; Ji, Y.; Qiu, B.; Zhan, M.; Wang, J. circFAM120B functions as a tumor suppressor in esophageal squamous cell carcinoma via the miR-661-5p/miR-30a-5p/REEP3 pathway. Cell Death Dis. 2022, 13, 361. [CrossRef] [PubMed]

82. Meng, L.; Zheng, Y.; Liu, S.; Ju, Y.; Ren, S.; Sang, Y.; Zhu, Y.; Gu, L.; Liu, F.; Zhao, Y.; et al. ZEB1 represses biogenesis of circ-DOCK5 to facilitate metastasis in esophageal squamous cell carcinoma via a positive feedback loop with TGF-beta. Cancer Lett. 2021, 519, 117–129. [CrossRef] [PubMed]

83. Fan, L.; Cao, Q.; Liu, J.; Zhang, J.; Li, B. Circular RNA profiling and its potential for esophageal squamous cell cancer diagnosis and prognosis. Mol. Cancer 2019, 18, 16. [CrossRef]

84. Wang, S.; Zhang, K.; Tan, S.; Xin, J.; Yuan, Q.; Xu, H.; Xu, X.; Liang, Q.; Christiani, D.C.; Wang, M.; et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies. Mol. Cancer 2021, 20, 13. [CrossRef]

85. Liu, S.; Lin, Z.; Rao, W.; Zheng, J.; Xie, Q.; Lin, Y.; Lin, X.; Chen, H.; Chen, Y.; Hu, Z. Upregulated expression of serum exosomal hsa_circ_0026611 is associated with lymph node metastasis and poor prognosis of esophageal squamous cell carcinoma. J. Cancer 2021, 12, 918–926. [CrossRef]

86. Qian, C.J.; Tong, Y.Y.; Wang, Y.C.; Teng, X.S.; Yao, J. Circ_0001093 promotes glutamine metabolism and cancer progression of esophageal squamous cell carcinoma by targeting miR-579-3p/glutaminase axis. J. Bioenerg. Biomembr. 2022, 54, 119–134. [CrossRef] [PubMed]
87. Wang, W.; Zhu, D.; Zhao, Z.; Sun, M.; Wang, F.; Li, W.; Zhang, J.; Jiang, G. RNA sequencing reveals the expression profiles of circRNA and identifies a four-circRNA signature acts as a prognostic marker in esophageal squamous cell carcinoma. Cancer Cell Int. 2021, 21, 151. [CrossRef] [PubMed]

88. Zhang, H.; Ju, L.; Hu, P.; Ye, J.; Yang, C.; Huang, J. Circular RNA 0014715 Facilitates Cell Proliferation and Inhibits Apoptosis in Esophageal Squamous Cell Carcinoma. Cancer Manag. Res. 2021, 13, 4735–4749. [CrossRef]

89. Xu, Z.; Tie, X.; Li, N.; Yi, Z.; Shen, F.; Zhang, Y. Circular RNA hsa_circ_000654 promotes esophageal squamous cell carcinoma progression by regulating the miR-149-5p/IL-6/STAT3 pathway. IUBMB Life 2020, 72, 426–439. [CrossRef]

90. Pan, Z.; Lin, J.; Wu, D.; He, X.; Zhang, L.; Wang, M. Hsa_circ_0006948 enhances cancer progression and epithelial-mesenchymal transition through the miR-490-3p/HMGAA2 axis in esophageal squamous cell carcinoma. Aging 2019, 11, 11937–11954. [CrossRef]

91. Li, X.; Song, L.; Wang, B.; Tao, C.; Shi, L.; Xu, M. Circ0120816 acts as an oncogene of esophageal squamous cell carcinoma by inhibiting miR-1305 and releasing TXNRD1. Cancer Cell Int. 2020, 20, 526. [CrossRef] [PubMed]

92. Hu, X.; Wu, D.; He, X.; Zhao, H.; He, Z.; Lin, J.; Wang, K.; Wang, W.; Pan, Z.; Lin, H.; et al. circGSK3beta promotes metastasis in esophageal squamous cell carcinoma by augmenting beta-catenin signaling. Mol. Cancer 2019, 18, 160. [CrossRef] [PubMed]

93. Yao, D.; Lin, S.; Chen, S.; Wang, Z. circH1PK3 regulates cell proliferation and migration by sponging microRNA-124 and regulating serine/threonine kinase 3 expression in esophageal squamous cell carcinoma. Bioengineer 2022, 13, 9767–9780. [CrossRef]

94. Shi, Y.; Fang, N.; Li, Y.; Guo, Z.; Jiang, W.; He, Y.; Ma, Z.; Chen, Y. Circular RNA LPAR3 sponges microRNA-198 to facilitate esophageal cancer migration, invasion, and metastasis. Cancer Sci. 2020, 111, 2824–2836. [CrossRef]

95. Yang, G.; Zhang, Y.; Lin, H.; Liu, J.; Huang, S.; Zhong, W.; Peng, C.; Du, L. lncRNA circ002984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis. Bioengineer 2022, 13, 10578–10593. [CrossRef] [PubMed]

96. Chen, X.; Jiang, J.; Zhao, Y.; Wang, X.; Zhang, C.; Zhan, L.; Deng, Z.; Zheng, Y. Circular RNA circNTRK2 facilitates the progression of esophageal squamous cell carcinoma through up-regulating NRP1 expression via miR-140-3p. J. Exp. Clin. Cancer Res. 2020, 39, 133. [CrossRef]

97. Guan, X.; Guan, X.; Yang, W.; Lan, T.; Cheng, T.; Cui, Y.; Yu, H. Circ_0003340 downregulation mitigates esophageal squamous cell carcinoma progression by targeting miR-940/PRKAA1 axis. Thorac. Cancer 2022, 13, 1164–1175. [CrossRef]

98. Song, H.; Xu, D.; Shi, P.; He, B.; Li, Z.; Ji, Y.; Agbeko, C.K.; Wang, J. Upregulated circ RNA hsa_circ_0003373 promotes cancer proliferation, migration, and invasion of esophageal squamous cell carcinoma. Cancer Manag. Res. 2019, 11, 1997–2006. [CrossRef]

99. Zhang, Z.; Lin, W.; Gao, L.; Chen, K.; Yang, C.; Zhan, L.; Peng, S.; Kang, M.; Lin, J. Hsa_circ_0004370 promotes esophageal cancer progression through miR-1294/LASP1 pathway. Biosci. Rep. 2019, 39, BSR20182377. [CrossRef]

100. Cao, S.; Chen, G.; Yan, L.; Li, L.; Huang, X. Contribution of dysregulated circRNA_100876 to proliferation and metastasis of esophageal squamous cell carcinoma. Onco Targets Ther. 2018, 11, 7385–7394. [CrossRef]

101. Chang, Z.; Fu, Y.; Jia, G.; Mao, S.; Song, L.; Zhang, W.; Zhao, R.; Qin, Y. Circ-SFMBT2 drives the malignant phenotypes of esophageal cancer by the miR-107-dependent regulation of SLCE1A5. Cancer Cell Int. 2021, 21, 495. [CrossRef] [PubMed]

102. Wang, Q.; Liu, H.; Liu, Z.; Yang, L.; Zhou, J.; Cao, X.; Sun, H. Circ-SC7A5, a potential prognostic circulating biomarker for detection of ESCC. Cancer Genet. 2020, 240, 33–39. [CrossRef] [PubMed]

103. Fang, N.; Shi, Y.; Fan, Y.; Long, T.; Shu, Y.; Zhou, J. circ_0072088 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Cancer by Absorbing miR-377. Biosci. Rep. 2020, 40, e24304. [CrossRef] [PubMed]

104. Fang, N.; Shi, Y.; Fan, Y.; Long, T.; Shu, Y.; Zhou, J. circ_0072088 Promotes Proliferation, Migration, and Invasion of Esophageal Squamous Cell Cancer by Absorbing miR-377. Biosci. Rep. 2020, 40, e24304. [CrossRef] [PubMed]

105. Zhao, Q.; Zhu, X.; Ke, J.M.; Su, X.Y.; Yi, J.; Wu, D.L.; Lin, J.; Deng, Z.Q. Circular RNA BMM1 Serves as a Potential Target for Diagnosis and Treatment in Esophageal Cancer. Technol. Cancer Res. Treat. 2021, 20, 1533038211030375. [CrossRef] [PubMed]

106. Wang, H.; Song, X.; Wang, Y.; Yin, X.; Liang, Y.; Zhang, T.; Xu, L.; Jiang, F.; Dong, G. circCTN1AP3-TP3-positive feedback loop suppresses malignant progression of esophageal squamous cell carcinoma. Cell Death Dis. 2020, 11, 1010. [CrossRef]

107. Wang, J.; Wang, Q.; Gong, Y.; Hu, Q.; Zhang, H.; Ke, S.; Chen, Y. Knockdown of circRNA circ_0087378 Represses the Tumorigenesis and Progression of Esophageal Squamous Cell Carcinoma Through Modulating the miR-140-3p/E2F3 Axis. Front. Oncol. 2020, 10, 607231. [CrossRef]

108. Zhang, Y.; Wang, Q.; Zhu, D.; Rong, J.; Shi, W.; Cao, X. Up-regulation of circ-SMAD7 inhibits tumor proliferation and migration in esophageal squamous cell carcinoma. Biomed. Pharmacother. 2019, 111, 596–601. [CrossRef]

109. Lin, J.; Song, T.; Li, C.; Mao, W. GSK-3β in DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy of cancer. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 2020, 1867, 118659. [CrossRef]

110. Liu, J.; Xue, N.; Guo, Y.; Niu, K.; Gao, L.; Zhang, S.; Gu, H.; Wang, X.; Zhao, D.; Fan, R. circRNA_100367 regulates the radiation sensitivity of esophageal squamous cell carcinomas through miR-217/Wnt5 pathway. Aging 2019, 11, 12412–12427. [CrossRef]

111. Liu, Z.H.; Lu, X.Y.; Wen, L.C.; You, C.W.; Jin, X.W.; Liu, J.Y. Hsa_circ_0014879 regulates the radiosensitivity of esophageal squamous cell carcinoma through miR-519-3p/CDC25A axis. Anti-Cancer Drugs 2022, 33, E349–E361. [CrossRef] [PubMed]

112. Su, H.; Lin, F.; Deng, X.; Shen, L.; Fang, Y.; Fei, Z.; Zhao, L.; Zhang, X.; Pan, H.; Xie, D.; et al. Profiling and bioinformatics analyses reveal differential circular RNA expression in radioresistant esophageal cancer cells. J. Transl. Med. 2016, 14, 225. [CrossRef] [PubMed]

113. Chang, N.; Ge, N.; Zhao, Y.; Yang, L.; Qin, W.; Cui, Y. Hsa_circ_0007142 contributes to cisplatin resistance in esophageal squamous cell carcinoma via miR-494-3p/LASPI1 axis. J. Clin. Lab. Anal. 2022, 36, e24304. [CrossRef] [PubMed]
114. Qu, F.; Wang, L.; Wang, C.; Yu, L.; Zhao, K.; Zhong, H. Circular RNA circ_0006168 enhances Taxol resistance in esophageal squamous cell carcinoma by regulating miR-194-5p/JMJD1C axis. Cancer Cell Int. 2021, 21, 273. [CrossRef] [PubMed]

115. Zou, F.W.; Yang, S.Z.; Li, W.Y.; Liu, C.Y.; Liu, X.H.; Hu, C.H.; Liu, Z.H.; Xu, S. circRNA_001275 upregulates Wnt7a expression by competitively sponging miR3703p to promote cisplatin resistance in esophageal cancer. Int. J. Oncol. 2020, 57, 151–160. [CrossRef]

116. Liu, Z.; Gu, S.; Wu, K.; Li, L.; Dong, C.; Wang, W.; Zhou, Y. circRNA-DOPEY2 enhances the chemosensitivity of esophageal cancer cells by inhibiting CPEB4-mediated Mcl-1 translation. J. Exp. Clin. Cancer Res. 2021, 40, 361. [CrossRef]

117. Zang, R.; Qiu, X.; Song, Y.; Wang, Y. Exosomes Mediated Transfer of Circ_0000337 Contributes to Cisplatin (CDDP) Resistance of Esophageal Cancer by Regulating JAK2 via miR-377-3p. Front. Cell Dev. Biol. 2021, 9, 673237. [CrossRef]

118. Liu, X.; Abraham, J.M.; Cheng, Y.; Wang, Z.; Wang, Z.; Zhang, G.; Ashktorab, H.; Smoot, D.T.; Cole, R.N.; Boronina, T.N.; et al. Synthetic Circular RNA Functions as a miR-21 Sponge to Suppress Gastric Carcinoma Cell Proliferation. Mol. Ther. Nucleic Acids. 2018, 13, 312–321. [CrossRef]